Biotech | January 07, 2022
Merck KGaA to acquire biopharma CDMO Exelead for $780 million
The transaction is expected to close in the first quarter of 2022
The transaction is expected to close in the first quarter of 2022
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
The medicine is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The acquisition complements and strengthens Merck’s cardiovascular pipeline
Subscribe To Our Newsletter & Stay Updated
